Welcome to our dedicated page for Incyte SEC filings (Ticker: INCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Incyte Genomics Inc (INCY) SEC filings page on Stock Titan aggregates regulatory documents for Incyte Corporation, a global biopharmaceutical company focused on Oncology and Inflammation & Autoimmunity. These filings provide structured insight into how the company reports its financial condition, governance changes and material events to the U.S. Securities and Exchange Commission.
Incyte’s common stock is listed on The Nasdaq Stock Market LLC under the symbol INCY, as disclosed in Form 8‑K reports. Investors can review current reports on Form 8‑K that cover topics such as quarterly financial results, executive and board transitions, inducement equity awards and key corporate agreements. For example, recent 8‑Ks describe leadership changes in the chief executive officer and chief financial officer roles, transition and employment agreements, and announcements of quarterly earnings press releases.
Alongside 8‑Ks, users can access Incyte’s annual reports on Form 10‑K and quarterly reports on Form 10‑Q (when available in the feed) to understand segment focus, risk factors, research and development priorities, and other disclosures that frame the company’s oncology and immunology strategy. These periodic reports typically detail the status of marketed products and pipeline programs, capital structure and significant accounting policies.
For those tracking management incentives and ownership, the filings page also links to insider transaction reports on Form 4 and related beneficial ownership disclosures, where present in EDGAR. These documents show grants of stock options, restricted stock units and performance shares, such as inducement awards and executive compensation packages referenced in Incyte’s current reports.
Stock Titan enhances this information by providing AI-powered summaries that explain the key points of lengthy filings, highlight notable changes and help readers interpret complex legal and financial language. Real‑time updates from EDGAR ensure that new INCY filings—whether earnings‑related, governance‑related or tied to material clinical and commercial developments—are quickly reflected, allowing investors, researchers and other stakeholders to review the underlying documents and AI insights in one place.
Incyte Corporation’s Executive Vice President and Head of Technical Operations reported several sales of company common stock. On December 16, 2025, the officer sold 833 shares at $97.42 per share and 53,175 shares at $97.29 per share. On December 17, 2025, the officer sold 4,323 shares at $97.26 per share. After these transactions, the officer reported beneficial ownership of 27,507 shares, which the filing explains includes shares issuable under previously reported restricted stock units and earned performance stock units that have not yet vested.
Incyte Corporation reported an insider stock sale by its Executive Vice President and Chief Scientific Officer. On 12/10/2025, the officer sold 5,553 shares of common stock at $95.58 per share. On 12/11/2025, they sold another 255 shares at $94.94 per share. After these transactions, the reporting person directly beneficially owns 60,011 common shares. A footnote also identifies 59,858 additional shares of common stock issuable under previously reported restricted stock units that have not yet vested.
Incyte Corp’s Executive Vice President & Chief Medical Officer reported several stock transactions in early
On
Incyte Corporation (INCY) reported insider stock transactions by its Principal Accounting Officer on a Form 4. The officer sold 169 shares of common stock on 11/21/2025 at $102 per share and 600 shares on 11/24/2025 at $103 per share. After these sales, the officer directly owned 23,573 shares of Incyte common stock.
The filing also notes that, including a July 15, 2025 grant, the officer holds an aggregate of 15,166 shares of common stock issuable from previously reported restricted stock units that have not yet vested. These transactions reflect personal trading activity by a company officer and ongoing equity-based compensation.
Incyte Corporation’s EVP & General Counsel filed a Form 4 reporting a small insider transaction. On 11/17/2025, the executive exercised an employee stock option to acquire 278 shares of common stock at $64.25 per share and on the same day sold 278 shares at $104.36 per share. After these transactions, the executive directly owned 26,569 shares of Incyte common stock and held 8,883 employee stock options. The filing also notes 25,913 shares of common stock underlying previously reported restricted stock units and earned performance units that are issuable but not yet vested.
Incyte Corporation (INCY) filed a Form 4 disclosing an insider sale. A director reported selling 187,500 shares of common stock on 11/10/2025 at a price of $105.46 per share. Following this transaction, the reporting person beneficially owns 329,646 shares, held directly.
The filing notes that this total includes 73,486 shares issuable from previously reported RSUs and earned performance shares that have not yet vested. No derivative securities were reported in Table II for this transaction. This is a routine insider ownership update and does not by itself indicate changes in company operations or strategy.
Incyte Corp (INCY): Form 4 insider activity. The company’s EVP & Chief Medical Officer reported option exercises and a same‑day sale on 11/05/2025.
The executive exercised options for 1,194 shares at $83.83, 2,995 shares at $95.76, and 1,044 shares at $95.76, then sold 5,233 shares at $102.20. Following these transactions, the executive beneficially owns 102,886 shares directly.
Footnotes note that 100,327 shares are issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. The exercised options were from grants that became exercisable per their original vesting schedules.
Incyte (INCY) insider activity: The company’s EVP & General Counsel reported a same‑day option exercise and sale on 11/04/2025. He exercised 598 employee stock options at $58.06 per share and sold 598 common shares at $101.36 per share.
Following these transactions, he directly owned 26,569 common shares. He also held 13,765 derivative securities (employee stock options) after the activity. In addition, the filing notes 25,913 shares of common stock are issuable pursuant to previously reported restricted stock units and earned performance units that have not vested.
Incyte Corp (INCY) reported an insider transaction on Form 4. The company’s EVP, Head of Incyte Intl, sold 3,074 shares of common stock on 11/03/2025 at $94.02 per share.
Following the sale, the reporting person beneficially owned 29,241 shares directly. This figure includes 26,167 shares issuable pursuant to previously reported RSUs that have not vested.
Incyte reported stronger Q3 results, with total revenue of $1.366 billion, up from $1.138 billion a year ago. Net income rose to $424.2 million (diluted EPS $2.11) from $106.5 million ($0.54). Year to date, revenue reached $3.634 billion and net income was $987.4 million, a sharp improvement from a loss in the prior year.
Growth was broad-based: JAKAFI revenue was $791.1 million, OPZELURA $188.0 million, and new contributions included NIKTIMVO at $45.8 million and ZYNYZ at $22.7 million. Royalty revenue increased to $171.1 million, led by JAKAVI royalties of $125.6 million. Milestone and contract revenue was $45.0 million.
Operating expense trends were favorable. R&D for the quarter was $506.6 million versus $573.2 million, and cost of product revenues was $99.0 million. For the nine months, results also reflect a $242.3 million contract dispute settlement benefit tied to resolved JAKAFI royalties with Novartis and a 50% reduction in the ongoing U.S. JAKAFI royalty rate starting January 1, 2025. Cash and cash equivalents were $2.455 billion, with marketable securities of $474.8 million. Shares outstanding were 196,322,703 as of October 21, 2025.